Cannabis Law Report
APRIL 21, 2022
The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment. April 5, 2022.
Canna Law Blog
JANUARY 3, 2023
Until recently, CBD resided in a legal penumbra where hemp was still scheduled on the federal Controlled Substances Act and could not be cultivated without a permit from the Drug Enforcement Administration (“DEA”). It’s not like the FDA is unaware of the massive unregulated CBD market that already exists in the U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 9, 2021
Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinical trials are currently under way. See Usona Institute, A Study of Psilocybin for Major Depressive Disorder (MDD) , Clinical Trial ID NCT03866174, available at [link].
CannaMD
AUGUST 8, 2020
Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential. In 1970, the U.S. This new bill allows broad hemp cultivation.
Cannabis Law Report
JUNE 4, 2021
As a graduate student, he received the IPMI Richard Rubin Memorial Scholarship in 2014 for his research in precious metals. However, Delta 8-THC is explicitly listed on the DEA 7370 Controlled Substance list, so it’s hard to imagine the cases ending in any other way than saying Delta 8-THC should be regulated like cannabis. . .
Cannabis Law Report
APRIL 8, 2022
This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Later that year, Doblin sued the DEA for the first time. Rick Doblin, Ph.D., and Michael Mithoefer, M.D., Lyle Craker, Ph.D.,
CannaMD
NOVEMBER 15, 2020
Drug Enforcement Agency (DEA) announced that it will evaluate 37 additional grower applications. One such rule requires that all growers turn over all marijuana and by-products to the DEA shortly after harvest. The DEA would then be the exclusive distributor. Furthermore, since 2014, the U.S. In August 2020, the U.S.
Expert insights. Personalized for you.
52 
Let's personalize your content